CAJ | 학술논문

噻替派治疗应用%白消安/治疗应用%阿糖腺苷/治疗应用/类似物和衍生物%白血病,非淋巴细胞,急性/预防和控制%移植预处理%造血干细胞移植%移植物抗宿主病噻替派治療應用%白消安/治療應用%阿糖腺苷/治療應用/類似物和衍生物%白血病,非淋巴細胞,急性/預防和控製%移植預處理%造血榦細胞移植%移植物抗宿主病
새체파치료응용%백소안/치료응용%아당선감/치료응용/유사물화연생물%백혈병,비림파세포,급성/예방화공제%이식예처리%조혈간세포이식%이식물항숙주병
Thiotepa/TU%Busulfan/TU%Vidarabine/TU/AA%Leukemia,nonlymphocytie,acute/PC%Transplantation conditioning%Hematopoietic stem cell transplantation%Graft vs host disease

目的探讨以氟达拉滨+白舒非+噻替哌作为预处理方案(FBT预处理方案),进行异基因外周血造血干细胞移植治疗难治/复发急性非淋巴细胞白血病的疗效及可行性.方法以FBT方案作为预处理方案,以环孢素A+骁悉预防移植物抗宿主病(GVHD),对7例难治/复发急性非淋巴细胞白血病患者进行HLA全相合异基因外周血造血干细胞移植.结果中位随访时间31个月,2例复发,5例患者无病存活.结论 FBT预处理方案复发率低,毒副作用轻,相关并发症少,患者耐受性好,对于难治/复发急性非淋巴细胞白血病患者而言,是一种值得进一步探讨的临床治疗方案.
목적 탐토이불체랍빈+백서비+새체고작위예처리방안(FBT예처리방안),진행이기인외주혈조혈간세포이식치료난치/복발급성비림파세포백혈병적료효급가행성.방법 이FBT방안작위예처리방안,이배포소A+효실예방이식물항숙주병(GVHD),대7례난치/복발급성비림파세포백혈병환자진행HLA전상합이기인외주혈조혈간세포이식.결과 중위수방시간31개월,2례복발,5례환자무병존활.결론 FBT예처리방안복발솔저,독부작용경,상관병발증소,환자내수성호,대우난치/복발급성비림파세포백혈병환자이언,시일충치득진일보탐토적림상치료방안.
Objective To evaluate the efficacy and feasibility of Flu/ivBu/Tl" conditioning regimen for the treatment of refractory or relapsed acute non-lymphocytic leukemia in patients receiving allogeneic hematopoietie stem cell transplantation. Methods Seven patients with refractory or relapsed acute non-lymphocytic leukemia received HLA identical peripheral blood hematopoietie stem cell transplantation (PBSCT) following Flu/ivBu/TY conditioning regimen, which consisted of fludarbine, busulfex and thiotepa. All patients received cyclos-porin A (CsA) and mycophenolet mofetil (MMF) for prophylaxis of graft - versus - host disease (GVHD). Results The Flu/IVBu/TT regimen was tolerated very well, without severe regimen related toxicity. In the 31-month median follow-up duration, 5 of 7 patients were a-live in disease-free situation. Conclusion The Flu/ivBu/TT conditioning regimen reduced transplantation-related toxicities and offered high long-term disease-free survival, and was tolerated very well. Allogeneie hematopoietie stem cell transplantation using Flu/ivBu/TT condition-ing regimen is a safe and effective option for the patients with refractory/relapsed acute non-lymphocytic leukemia.